查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584742

抗忧郁症市场：按药物类别、适应症、给药途径、分销管道划分 - 全球预测 2025-2030

Antidepressants Drugs Market by Drug Class, Indication, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗忧郁症市值为207.1亿美元，预计到2024年将达到224.4亿美元，复合年增长率为9.85%，到2030年将达到399.9亿美元。

抗忧郁症包括多种药物，包括 SSRIs、SNRIs、MAOIs 和三环抗忧郁药物，主要用于治疗忧郁症和相关疾病，如焦虑症、强迫性精神官能症和创伤后压力症候群 (PTSD)。这些药物透过改变大脑中的化学失衡来发挥作用，而大脑中的化学失衡被认为与情绪变化和情绪状态有关。由于精神健康障碍盛行率上升、意识提高以及围绕精神健康治疗的耻辱感减少，抗忧郁症的需求正在增加。这些药物已广泛应用于各种最终用户，包括医院、诊所和家庭环境。关键的成长要素包括全球患者人数的不断扩大以及药物配方和药物传递系统的进步，以提高疗效并减少副作用。此外，远端医疗和线上心理健康服务等趋势正在扩大抗忧郁症的供应和可近性。然而，这个市场在某些文化中仍然面临局限性，包括心理健康药物仍然存在的耻辱、潜在的副作用以及心理治疗和生活方式干预等替代疗法的可用性。从潜在商机来看，个人化医疗以及开发副作用更少、起效更快的药物有很大的技术创新空间。此外，在生物标记发现方面存在更好的诊断和治疗工具以及在药物发现过程中使用人工智慧的机会。然而，他们面临严格的监管要求、专利到期以及先进药物高成本等挑战。神经可塑性和遗传标记等研究领域可能会出现创新治疗方法，而公司可能会专注于透过策略联盟和合作研究来扩大区域市场。该市场竞争激烈，有多家大型製药公司和快速成长的学名药製造商。

主要市场统计
基准年[2023] 207.1亿美元
预测年份 [2024] 224.4亿美元
预测年份 [2030] 399.9亿美元
复合年增长率（%） 9.85%

市场动态：揭示快速发展的抗忧郁症市场的关键市场洞察

供需的动态交互作用正在改变抗忧郁症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 创伤后压力症候群（PTSD）、强迫性精神官能症和焦虑症的增加
    • 积极的政府措施和宣传活动来解决心理健康问题
    • 精神卫生机构和专业人员数量的增加
  • 市场限制因素
    • 与抗忧郁症相关的副作用和费用
  • 市场机会
    • 开发新型抗忧郁症的创新解决方案
    • 增加新药的监管核准和增加 SSRIs 的使用
  • 市场挑战
    • 围绕心理健康治疗的社会耻辱

波特的五力：驾驭抗忧郁症市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗忧郁症市场的外部影响

外部宏观环境因素在塑造抗忧郁症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗忧郁症市场的竞争状况

抗忧郁症市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV抗忧郁症市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估抗忧郁症市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製抗忧郁症市场的成功之路

抗忧郁症市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 创伤后压力症候群 (PTSD)、强迫症 (OCD) 和焦虑症的发生率增加
      • 关于心理健康问题的有利政府措施和宣传活动
      • 心理健康机构和专业人员的增加
    • 抑制因素
      • 与抗忧郁症相关的副作用和费用
    • 机会
      • 新开发抗忧郁症的创新解决方案
      • 新药的监管核准增加和 SSRI 药物的使用增加
    • 任务
      • 围绕心理健康治疗的社会耻辱
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的抗忧郁症市场

  • 单胺氧化酵素抑制剂
  • 再回收抑制剂
  • 选择性血清素再回收抑制剂
  • 血清素拮抗剂
  • 正肾上腺素再回收抑制剂
  • 三环抗忧郁药物

抗忧郁症依适应症分類的抗忧郁药市场

  • 焦虑症
  • 注意力不足过动症
  • 重度忧郁症

抗忧郁症市场：依给药途径

  • 可注射的
  • 口服

第九章抗忧郁症市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第10章美洲抗忧郁症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太抗忧郁症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的抗忧郁症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Alembic Pharma核准美国FDA 批准销售非专利抗忧郁症
    • 完成 CinCor Pharma 的收购
    • Zydus核准美国食品药物管理局批准用于治疗忧郁症的学名药
    • RA Capital 支持寻求更好抗忧郁症的新Start-Ups
    • Autobahn筹集资金开发忧郁症治疗药物ABX-002
    • Axsome Therapeutics 宣布 FDA核准AUVELITY，这是第一个也是唯一一个用于治疗成人重度忧郁症的口服 NMDA 受体拮抗剂
    • Genetika+ ​​赢得了着名的欧洲资助，并将忧郁症药物匹配平台推向市场
    • Osmind 获得 4000 万美元投资，支持心理健康研究和治疗
    • Sun Pharma 计划在灵北 (Lundbeck) 的独家专利许可下在印度推出Vortioxetine)版本
    • 艾伯维 (AbbVie) 收购 Syndesi Therapeutics 以加强神经科学产品组合
    • 印度颗粒公司获得美国FDA核准非专利抗忧郁症
  • 战略分析和建议

公司名单

  • AN Pharmacia Laboratories Pvt. Ltd.
  • AbbVie Inc.
  • Alkermes PLC
  • Angelini Pharma Spa
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • CAPLYTA by Intra-Cellular Therapies, Inc.
  • Divi's Laboratories Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Eridanus Healthcare
  • H. Lundbeck A/S
  • Jabs Biotech Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • La Renon Healthcare Pvt. Ltd.
  • Lupin Ltd.
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Neurocon Inc.
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi SA
  • Somacare
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Wellona Pharma
Product Code: MRR-742BD517AEC4

The Antidepressants Drugs Market was valued at USD 20.71 billion in 2023, expected to reach USD 22.44 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 39.99 billion by 2030.

Antidepressant drugs, which encompass a broad range of medications such as SSRIs, SNRIs, MAOIs, and tricyclic antidepressants, are primarily designed to manage depression and associated disorders like anxiety, OCD, and PTSD. These medications function by altering chemical imbalances in the brain, which are thought to be responsible for mood changes and emotional states. The necessity for antidepressant drugs has been increasing, driven by the rising prevalence of mental health disorders, increased awareness, and reduced stigma surrounding mental health treatment. These drugs find application across various end-users, including hospitals, clinics, and household settings, making them widely accessible. Key growth factors include an expanding demographic of patients across the globe and advancements in drug formulations and delivery systems that improve efficacy and reduce side effects. Additionally, trends like telemedicine and online mental health services are expanding the reach and accessibility of antidepressants. However, the market faces limitations such as the stigma still attached to mental health medication in some cultures, potential side effects, and the existence of alternative therapies like psychotherapy and lifestyle interventions. Among potential opportunities, there is significant room for innovation in personalized medicine and the development of drugs with fewer side effects and quicker onset of action. Furthermore, opportunities exist in exploring biomarkers for better diagnostic and treatment tools and leveraging artificial intelligence for drug discovery processes. Nonetheless, the market faces challenges like stringent regulatory requirements, patent expirations, and the high cost of advanced medications. Research areas such as neuroplasticity and genetic markers may yield innovative treatments, while companies might focus on regional market expansion through strategic partnerships and collaborations. The nature of the market is highly competitive, characterized by the presence of several large pharmaceutical companies and growing generic drug manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 20.71 billion
Estimated Year [2024] USD 22.44 billion
Forecast Year [2030] USD 39.99 billion
CAGR (%) 9.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antidepressants Drugs Market

The Antidepressants Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of PTSD, OCD, and anxiety issues
    • Favorable government initiatives and campaigns for mental health problems
    • Rise in number of mental health institutions and professionals
  • Market Restraints
    • Associated side effects and cost of antidepressants drugs
  • Market Opportunities
    • Innovative solutions for the development of novel antidepressants drugs
    • Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
  • Market Challenges
    • Social stigma surrounding mental health treatments

Porter's Five Forces: A Strategic Tool for Navigating the Antidepressants Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antidepressants Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antidepressants Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antidepressants Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antidepressants Drugs Market

A detailed market share analysis in the Antidepressants Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antidepressants Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antidepressants Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antidepressants Drugs Market

A strategic analysis of the Antidepressants Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antidepressants Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Angelini Pharma S.p.a., Apotex Inc., AstraZeneca PLC, Biogen Inc., Bristol Myers Squibb Company, CAPLYTA by Intra-Cellular Therapies, Inc., Divi's Laboratories Limited, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Eridanus Healthcare, H. Lundbeck A/S, Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Mallinckrodt PLC, Merck & Co., Inc., Midas Pharma GmbH, Neurocon Inc., Organon & Co., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Somacare, SteriMax Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Antidepressants Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Monoamine Oxidase Inhibitors, Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Serotonin Antagonist, Serotonin-Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants.
  • Based on Indication, market is studied across Anxiety Disorders, Attention Deficit Hyperactivity Disorder, and Major Depressive Disorder.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of PTSD, OCD, and anxiety issues
      • 5.1.1.2. Favorable government initiatives and campaigns for mental health problems
      • 5.1.1.3. Rise in number of mental health institutions and professionals
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects and cost of antidepressants drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative solutions for the development of novel antidepressants drugs
      • 5.1.3.2. Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Social stigma surrounding mental health treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antidepressants Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Monoamine Oxidase Inhibitors
  • 6.3. Reuptake Inhibitors
  • 6.4. Selective Serotonin Reuptake Inhibitors
  • 6.5. Serotonin Antagonist
  • 6.6. Serotonin-Norepinephrine Reuptake Inhibitors
  • 6.7. Tricyclic Antidepressants

7. Antidepressants Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety Disorders
  • 7.3. Attention Deficit Hyperactivity Disorder
  • 7.4. Major Depressive Disorder

8. Antidepressants Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Antidepressants Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Antidepressants Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antidepressants Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antidepressants Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Alembic Pharma gets USFDA nod to market generic antidepressant drug
    • 13.3.2. Acquisition of CinCor Pharma complete
    • 13.3.3. Zydus gets USFDA nod to market generic medicine for treating depression
    • 13.3.4. RA Capital backs another startup hunting for a better antidepressant
    • 13.3.5. Autobahn raises funds for ABX-002 advancement to treat depression
    • 13.3.6. Axsome Therapeutics Announces FDA Approval of AUVELITY, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
    • 13.3.7. Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
    • 13.3.8. Osmind scores $40M investment to aid in mental health research and treatment
    • 13.3.9. Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
    • 13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
    • 13.3.11. Granules India gets USFDA approval for generic antidepressant drug
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. A. N. Pharmacia Laboratories Pvt. Ltd.
  • 2. AbbVie Inc.
  • 3. Alkermes PLC
  • 4. Angelini Pharma S.p.a.
  • 5. Apotex Inc.
  • 6. AstraZeneca PLC
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company
  • 9. CAPLYTA by Intra-Cellular Therapies, Inc.
  • 10. Divi's Laboratories Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eisai Co., Ltd.
  • 13. Eli Lilly and Company
  • 14. Eridanus Healthcare
  • 15. H. Lundbeck A/S
  • 16. Jabs Biotech Pvt. Ltd.
  • 17. Johnson & Johnson Services, Inc.
  • 18. La Renon Healthcare Pvt. Ltd.
  • 19. Lupin Ltd.
  • 20. Mallinckrodt PLC
  • 21. Merck & Co., Inc.
  • 22. Midas Pharma GmbH
  • 23. Neurocon Inc.
  • 24. Organon & Co.
  • 25. Otsuka Pharmaceutical Co., Ltd.
  • 26. Pfizer Inc.
  • 27. Sandoz International GmbH by Novartis AG
  • 28. Sanofi S.A.
  • 29. Somacare
  • 30. SteriMax Inc.
  • 31. Sun Pharmaceutical Industries Limited
  • 32. Takeda Pharmaceutical Co. Ltd.
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. UCB S.A.
  • 35. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. ANTIDEPRESSANTS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIDEPRESSANTS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIDEPRESSANTS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIDEPRESSANTS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023